Table 2 Summary of neonatal M20 Tg mice injected with αS proteins a
From: Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein
Mouse strain | Inoculums | Age at harvest | Number of mice | Pathological findings |
|---|---|---|---|---|
M20 (WT αS) | fib αS (2 μl of 1 mg/ml) | 1 month | 7 | No inclusions |
M20 (WT αS) | fib αS (2 μl of 1 mg/ml) | 2 months | 5 | No inclusions |
M20 (WT αS) | fib αS (2 μl of 1 mg/ml) | 4 months | 3 | No inclusions |
M20 (WT αS) | fib αS (2 μl of 1 mg/ml) | 8 months | 4 | 4 of 4 mice show sparse cortical pathology |
M20 (WT αS) | fib αS (5 μl of 5 mg/ml) | 1 month | 4 | 3 of 4 mice show sparse cortical pathology |
M20 (WT αS) | fib αS (5 μl of 5 mg/ml) | 2 months | 5 | 4 of 5 mice show sparse cortical pathology |
M20 (WT αS) | fib αS (5 μl of 5 mg/ml) | 4 months | 3 | 2 of 3 mice show sparse cortical pathology |
M20 (WT αS) | fib αS (5 μl of 5 mg/ml) | 8 months | 12 | 12 of 12 mice show abundant pathologyb |
M20 (WT αS) | Δ71-82 αS (2 μl of 1 mg/ml) | 1 month | 5 | No inclusions |
M20 (WT αS) | Δ71-82 αS (2 μl of 1 mg/ml) | 2 months | 5 | No inclusions |
M20 (WT αS) | Δ71-82 αS (2 μl of 1 mg/ml) | 4 months | 3 | No inclusions |
M20 (WT αS) | Δ71-82 αS (2 μl of 1 mg/ml) | 8 months | 3 | No inclusions |
M20 (WT αS) | Δ71-82 αS (5 μl of 5 mg/ml) | 1 month | 7 | No inclusions |
M20 (WT αS) | Δ71-82 αS (5 μl of 5 mg/ml) | 2 months | 7 | No inclusions |
M20 (WT αS) | Δ71-82 αS (5 μl of 5 mg/ml) | 8 months | 6 | 2 out of 6 mice show abundant pathologyb |